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Silent Hypoxia in COVID-19:
What is Old is New Again!
Sir,
With Coronavirus disease of 2019 (COVID-19) pandemic, silent
hypoxemia (significant hypoxemia without dyspnea) is a pheno-
menon  to  understand  with  associated  shunt  physiology,
preserved lung compliance, and lack of dead space.1 It applies
to any lung pathology which causes a reserved amount of shunt
while saving the rest of the lung such as lobar pneumonia or
atelectasis. Silent hypoxemia can last forever but individuals
could present to a healthcare facility with this condition occasio-
nally. COVID-19 made us to think about this forgotten approach.
COVID-19 lung injury includes viral medial inflammation, alve-
olar  epithelial  dysfunction,  impaired  surfactant,  alveolar
collapse, and increased pulmonary artery pressure patients.1,2
The  disease  process  is  been  treated  as  acute  respiratory
distress  syndrome  (ARDS)  but  it  is  not  typical  ARDS.  With
normal lung compliance and many of them not in respiratory
distress, hypoxemia does not correlate with their clinical condi-
tion.1-2 Patients often presents in stable condition where they
are able to speak full sentences with oxygen saturation of 80%,
hence pulse oximetry may be a marker for respiratory dist-
ress.1,2
Intra-pulmonary shunting, relatively preserved lung complian-
ce, lack of excessive dead space, lack of substantial pulmonary
embolism  or  microvascular  thrombosis  and  dysfunctional
hypoxemic vasoconstriction are the key features.1,2 COVID-19
patients faced slow onset severe hypoxemia with hypocapnia.
Atelectasis,  obesity,  elderly  and  underlying  structural  lung
disease could be the predisposing factors for rapid deteriora-
tion in the clinical condition.1,2 COVID-19 related hypoxemia is
different as patient is not subjectively tachypneic but patterns
of respiration are making patients to have an enhanced respira-
tory drive and minute ventilation.1,2 In compensation, patients
have increased carbon dioxide (CO2) clearance which keeps
them away from getting short of breath.1,2
Stages of silent hypoxia described as zones divided into subclin-
ical, detection and high mortality.1,2 Subclinical zone is where
oxygen saturation is normal with normal respiratory rate. Detec-
tion zone is where there is gradual decline in oxygen saturation
with  no  subjective  shortness  of  breath  but  respiratory  rate
started to rise with progressive self-inflicted lung injury (SILI).
This is the zone for intervention; and dramatic results can be
seen if treatment is initiated.1,2 High mortality is the zone where
oxygen saturation drops with increasing subjective shortness of
breath. This is the zone where type H physiology transition with
respiratory failure can occur.1
Silent  hypoxemia  can  become a  severe  form of  hypoxemia
when there is a poor response to supplemental oxygen. This had
been  seen  in  aviation  science3,4;  and  COVID-19  made  us  to
rethink about this physiology. Firstly, with oxygenation, hypox-
emia  occurs  when  blood  from  right  ventricle  goes  into  left
ventricle without being oxygenated.1,2,5 It is due to ventilation
perfusion  mismatch;  hence,  the  net  result  is  hypoxemia.
Increasing  inhaled  oxygen  concentration  can  be  used  here.
Secondly there is the shunt physiology such anatomic abnormal-
ities or dysfunctional parts of lung.1-4 Any patient with desatura-
tion despite high supplemental oxygen likely has a shunt. CO2
clearance rely on amount of gas exchange with key reliance on
dead space such as scarred alveoli due to ARDS or in case pulmo-
nary embolism where there is gas exchange but no CO2 clear-
ance.1-3 Increasing dead space means patient must inhale more
gas to maintain the same CO2. Silent hypoxemia with normal
work of breathing occurs when there is right to left shunt, no
excessive dead space, normal lung compliance and lung resis-
tance.3,4
Management of silent hypoxemia in COVID-19 does not require
intubation. Personal protection equipment should be the initial
consideration.  Treatment  options  included  high  flow  nasal
cannula (HFNC) with surgical facemask over patient’s mouth,
awake-proning and repositioning (left lateral, sitting and right
lateral)  to  improve  the  saturation  to  90%.3,4  Awake  proning
showed feasibility in the times of scarce resources and shortage
of ventilators.  Nasal cannula with oxygen saturation goal of
88-92% is been reported in the literature. Continuous positive
airway pressure therapy (CPAP) is another option before intuba-
tion. Airway pressure release ventilation (APRV), conventional
low tidal-volume ventilation, permissive hypercapnia and opti-
mization of metabolic acid/base status and inhaled pulmonary
vasodilators are further treatment modalities.4,5
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